سعر ليتاك 10 مجم 5 فيال 2023

Litak cladribine 2 mg/ml solution for subcutaneous injection, 10 mg/5 ml per vial, pack of 5 vials (Lipomed; imported by Egyptian Pharmaceutical Trading Company); purine nucleoside analogue for hairy cell leukaemia.

• Treatment of hairy cell leukaemia.Population: Adults (contraindicated under 18 years)European Medicines Agency (EPAR)

• Very common: myelosuppression with severe neutropenia, thrombocytopenia and anaemia, severe immunosuppression/lymphopenia, infections, fever (up to 64%), decreased appetite, headache, dizziness and purpura; also nausea, vomiting, diarrhoea, fatigue and rash.International label, same product · European Medicines Agency (EPAR)

• Hypersensitivity to cladribine or excipients; pregnancy and lactation; age under 18 years; moderate to severe renal (CrCl 50 ml/min or less) or hepatic (Child-Pugh above 6) impairment; concomitant use of other myelosuppressive medicines.International label, same product · European Medicines Agency (EPAR)

• Myelosuppression and long-lasting immunosuppression/lymphocytopenia with opportunistic infections; monitor blood counts closely during and for 2-4 months after treatment; give irradiated blood components to prevent transfusion-associated graft-versus-host disease.International label, same product · European Medicines Agency (EPAR)
• Progressive multifocal leukoencephalopathy (including fatal cases) reported 6 months to several years after treatment; consider PML with new neurological, cognitive or behavioural symptoms and stop treatment if suspected.International label, same product · European Medicines Agency (EPAR)
• Second malignancies (3.4% of 232 Litak-treated HCL patients over 10 years); regular monitoring required. Tumour lysis prevention with allopurinol and hydration in high tumour burden.International label, same product · European Medicines Agency (EPAR)

• Other myelosuppressive medicinesMust not be used concomitantly (increased haematological toxicity and bone-marrow suppression).European Medicines Agency (EPAR)
• Other nucleoside analogues (e.g. fludarabine, 2'-deoxycoformycin)Possible cross-resistance; simultaneous administration not advisable.European Medicines Agency (EPAR)
• CorticosteroidsIncrease the risk of severe infections; should not be given concomitantly.European Medicines Agency (EPAR)

• Contraindicated in pregnancy: cladribine causes serious birth defects (teratogenic and mutagenic in animal and in vitro studies); women of childbearing potential must use effective contraception during treatment and for 6 months after the last dose.International label, same product · European Medicines Agency (EPAR)
• Cladribine is excreted in human milk (limited case data); breastfeeding is contraindicated during treatment and for 6 months after the last dose.International label, same product · European Medicines Agency (EPAR)

• Cladribine: Prodrug phosphorylated intracellularly (mainly in lymphocytes) to CdATP, which is incorporated into DNA, blocks DNA synthesis and repair and inhibits ribonucleotide reductase, causing cell death in dividing and resting cells.